Christopher R. Fenimore, Executive Vice President Finance and CFO of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), filed a Form 4 on August 20, 2026, disclosing transactions in common stock and a non-qualified stock option dated August 18, 2026.
Key Highlights
- Option exercise: Fenimore exercised a non-qualified stock option (transaction code M) covering 6,283 shares of common stock at an exercise price of $381.92 per share on August 18, 2026.
- Shares withheld for taxes: 4,599 shares were disposed of (transaction code F) at $813.47 per share on August 18, 2026.
- Direct ownership following transactions: Fenimore held 19,984 shares of common stock directly after the reported transactions.
- Remaining options: 6,000 non-qualified stock options with an exercise price of $381.92 and an expiration date of December 16, 2026, remained beneficially owned directly following the transactions.
- Indirect holdings: Fenimore also holds 1,574 shares via a 401(k) plan, 1,897 shares via a trust for the benefit of his spouse, and 25 shares each in two separate trusts for a daughter and a son.
Regeneron CFO's August 2026 Option Exercise and Share Disposition Details
According to the filing, Fenimore held the title of EVP Finance CFO at Regeneron Pharmaceuticals, Inc. at the time of the reported transactions. On August 18, 2026, he exercised a non-qualified stock option for 6,283 shares at a conversion price of $381.92 per share, recorded under transaction code M. The filing notes that the stock option award "vested in four equal annual installments, commencing one year after the date of grant." Following the exercise, 6,000 options under the same grant remained outstanding with an expiration date of December 16, 2026.
On the same date, the filing reports that 4,599 shares were disposed of at $813.47 per share under transaction code F, a code typically used for shares withheld for payment of taxes in connection with a vesting or exercise event. After both transactions, Fenimore's direct beneficial ownership stood at 19,984 shares of common stock, according to the filing.
In addition to directly held shares, the filing discloses several indirect ownership positions. A total of 1,574 shares are held through a 401(k) plan. The filing also identifies 1,897 shares held in a trust for the benefit of Fenimore's spouse, for which both Fenimore and his spouse serve as trustees. Two additional trusts hold 25 shares each, designated for a daughter and a son, respectively.
What Was Disclosed
The Form 4 filed August 20, 2026, discloses that Regeneron CFO Christopher R. Fenimore exercised 6,283 stock options and disposed of 4,599 shares on August 18, 2026, resulting in direct ownership of 19,984 common shares and 6,000 remaining options.




Please wait processing your request...